Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Moodys
Merck
Harvard Business School

Last Updated: December 3, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for CUDC-101


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug CUDC-101?

CUDC-101 is an investigational drug.

There have been 12 clinical trials for CUDC-101. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2016.

The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Head and Neck Neoplasms. The leading clinical trial sponsors are Curis, Inc., National Cancer Institute (NCI), and Rahul Aggarwal.

There are two hundred and fifty-three US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for CUDC-101
TitleSponsorPhase
The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis.Aarhus University HospitalPhase 1
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid CancerNational Cancer Institute (NCI)Phase 2
Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor MalignanciesNational Cancer Institute (NCI)Phase 1/Phase 2

See all CUDC-101 clinical trials

Clinical Trial Summary for CUDC-101

Top disease conditions for CUDC-101
Top clinical trial sponsors for CUDC-101

See all CUDC-101 clinical trials

US Patents for CUDC-101

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CUDC-101 ⤷  Try it Free Histone deacetylase inhibitors and methods for use thereof REACTION BIOLOGY CORP. (Malvern, PA) ⤷  Try it Free
CUDC-101 ⤷  Try it Free Anti-CS1 antibodies and antibody drug conjugates AbbVie Biotherapeutics Inc. (Redwood City, CA) ⤷  Try it Free
CUDC-101 ⤷  Try it Free Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III Frequency Therapeutics, Inc. (Woburn, MA) ⤷  Try it Free
CUDC-101 ⤷  Try it Free Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections EMORY UNIVERSITY (Atlanta, GA) ⤷  Try it Free
CUDC-101 ⤷  Try it Free Methods and compositions for treating antiprogestin-resistant cancers FUNDACION SALES (Capital Federal, AR) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CUDC-101

Drugname Country Document Number Estimated Expiration Related US Patent
CUDC-101 World Intellectual Property Organization (WIPO) WO2017030892 2035-08-14 ⤷  Try it Free
CUDC-101 Australia AU2015339012 2034-10-31 ⤷  Try it Free
CUDC-101 Brazil BR112017008945 2034-10-31 ⤷  Try it Free
CUDC-101 Canada CA2966005 2034-10-31 ⤷  Try it Free
CUDC-101 European Patent Office EP3212668 2034-10-31 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Moodys
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.